3 results
We hypothesize that the CardioMEMS HF system will be safe and superior to standard care in improving the quality of life and health status in patients with chronic HF in the Netherlands. Additionally, we hypothesize the CardioMEMS HF system is cost-…
Elinzanetant is an investigational compound. It is not approved for sale. That means it can only be used in studies like this one. Elinzanetant has been extensively tested in the laboratory. It has also been already administered to approximately 300…
Cohort ATo compare the CRR for the combination of pembrolizumab + BCG versus BCG alone in participants with CIS.Cohort B- To compare the EFS between participants who receive pembrolizumab + BCG (reduced maintenance) versus BCG alone- To compare the…